摘要
目的探讨替雷利珠单抗联合白蛋白结合型紫杉醇和替吉奥二线治疗晚期胃癌的效果。方法选取2020年1月至2023年1月宝鸡市陈仓医院肿瘤科收治的100例晚期胃癌患者,随机将其分为对照组和观察组,各50例。对照组给予白蛋白结合型紫杉醇和替吉奥二线治疗,观察组在对照组基础上给予替雷利珠单抗治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的癌胚抗原(CEA)、糖类抗原72-4(CA72-4)及糖类抗原199(CA199)水平低于对照组(P<0.05)。治疗后,观察组的CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。两组的不良反应发生率无明显差异(P>0.05)。结论替雷利珠单抗联合白蛋白结合型紫杉醇和替吉奥二线治疗晚期胃癌患者有助于提高治疗效果,降低肿瘤标志物水平,改善免疫功能,值得推广。
Objective To investigate the effect of tislelizumab combined with albumin bound paclitaxel and tegafur in the second line treatment of advanced gastric cancer.Methods A total of 100 patients with advanced gastric cancer admitted in the oncology department of Baoji Chencang Hospital from January 2020 to January 2023 were selected and randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with albumin bound paclitaxel and tegafur in the second line treatment,and the observation group was treated with tislelizumab on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 72-4(CA72-4)and carbohydrate antigen 199(CA199)in the observation group were lower than those in the control group(P<0.05).After treatment,CD4^(+)and CD4^(+)/CD8^(+)in the observation group were higher than those in the control group,and CD8^(+)was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Tislelizumab combined with albumin bound paclitaxel and tegafur in the second line treatment of patients with advanced gastric cancer is helpful to improve the therapeutic effect,reduce the levels of tumor markers,and improve immune function,which is worthy of promotion.
作者
李艳芳
张莉霞
LI Yanfang;ZHANG Lixia(Oncology Department,Baoji Chencang Hospital,Baoji 721300;Oncology Department,Xi'an Daxing Hospital,Xi'an 710002,China)
出处
《临床医学研究与实践》
2024年第29期51-54,共4页
Clinical Research and Practice
